267,985 Shares in Sana Biotechnology, Inc. $SANA Purchased by Rafferty Asset Management LLC

Rafferty Asset Management LLC bought a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 267,985 shares of the company’s stock, valued at approximately $951,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Sana Biotechnology by 49.8% during the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the period. Woodline Partners LP raised its position in Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after purchasing an additional 90,515 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after purchasing an additional 9,501 shares during the last quarter. Savant Capital LLC purchased a new position in shares of Sana Biotechnology during the 2nd quarter worth $172,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Sana Biotechnology during the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

More Sana Biotechnology News

Here are the key news stories impacting Sana Biotechnology this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $7.00 price target on SANA even as it trimmed estimates — that continued institutional support can limit downside and suggests upside potential if execution improves. MarketBeat SANA
• Neutral Sentiment: Sana presented at the TD Cowen 46th Annual Health Care Conference (transcript available). Conference appearances increase management visibility to investors; the stock reaction will depend on any new data or timeline updates disclosed in the talk. TD Cowen Presentation Transcript
• Negative Sentiment: HC Wainwright cut EPS estimates across multiple quarters and out years (Q1–Q4 2026 and FY2026–2030 were revised lower), signaling slower expected progress or higher near-term spend — these reductions pressure the stock by lowering near- and medium-term earnings visibility. MarketBeat SANA (HC Wainwright notes)
• Negative Sentiment: Zacks downgraded SANA from “strong-buy” to “hold,” removing a strong buy-side endorsement and likely contributing to selling pressure from retail/quant strategies that track analyst momentum. Zacks TickerReport
• Negative Sentiment: Sana recently reported an EPS miss for the quarter (reported March 3), which combined with the analyst downgrades increases near-term uncertainty around execution and cash runway — a key concern for biotech investors. MarketBeat SANA (earnings)
• Negative Sentiment: A TipRanks piece highlights a newly disclosed risk tied to AI adoption (data, compliance, reputational risks). While not an immediate earnings driver, rising compliance risk can raise operating costs or distract management if issues emerge. TipRanks: AI Risk

Analyst Ratings Changes

A number of research analysts have commented on SANA shares. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. HC Wainwright cut their target price on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday. Wedbush raised their price target on Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.83.

Sana Biotechnology Stock Down 7.6%

NASDAQ SANA opened at $3.15 on Friday. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $6.55. The firm has a 50 day moving average of $4.25 and a two-hundred day moving average of $4.13. The stock has a market capitalization of $840.64 million, a PE ratio of -3.25 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.